// App-Quantinova.ai

: Real-World Experience of Switching from Deferasirox Dispersible to Film-Coated Tablets: Impact on Adherence to Chelation Therapy, Iron Overload and Renal Function

Researchers

Presenter

  • Simon Cheesman

Principal Investigators

  • Raakhee Shah

  • Sara Trompeter

  • Perla Eleftheriou

  • Bernadette Hylton

  • Maciej W Garbowski

  • John Porter

Medical Centers

  • NHS Foundation Trust, London, United Kingdom

  • Department of Urology, King's College Hospital NHS Foundation Trust, London, United Kingdom

  • King's College Hosptial NHS Foundation Trust, London, United Kingdom

  • University College London Hospitals NHS Trust, London, United Kingdom

  • Kings College London, London, United Kingdom

  • Department of Medical Oncology, University College London Hospital, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Genetic Disorder

Disease

  • Hemochromatosis

Biomarkers

  • Creatinine

Drug/Treatment

  • Deferasirox

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved